Specialty Management: Keeping Up with Runaway Innovation
Contact Hours: 1.5 | Activity Type: Knowledge-based | ACPE UAN: 0233-0000-18-064-L04-P
Please note that this session has a sister roundtable session titled, RT4: “Best Practices in Operationalizing and Improving Biosimilar Uptake”, taking place today from 4:45 pm to 5:45 pm in room Anaheim. Space is limited on a first come first served basis for the first 30 attendees.
Although biosimilars have been on the market for some time, payers continue to face many challenges in implementation. However, some organizations have been able to overcome these barriers. For instance, Inflectra (infliximab-dyyb), biosimilar to Remicade (infliximab), was approved in 2016, but has limited uptake in the United States. Kaiser Permanente was one of the few health systems to implement the use of Inflectra starting in 2017. Today, Kaiser Permanente Northwest has 90% Inflectra utilization compared to 10% Remicade utilization.
This session will discuss the biosimilar experience and barriers to uptake across managed care pharmacy. The session will also take a deeper dive into a case study of Kaiser Permanente’s experience with Inflectra (infliximab-dyyb) in rheumatology, dermatology, and gastroenterology, and share lessons learned with other payers facing the same challenges with biosimilar conversions.
At the completion of this activity, participants should be able to: